A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Trial ID or NCT#
NCT00631462
Status
NOT RECRUITING
Purpose
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Official Title
A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia) - At least 18 years of age. - ECOG PS 0, 1, or 2.
Exclusion Criteria:
- - Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug. - Major surgery or radiation therapy within 28 days prior to initiation of study drug.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Andrea Linder
6507254047
View on ClinicalTrials.gov
